Source: iQoncept / Shutterstock
Immunovant (NASDAQ:IMVT) recently disclosed its performance for the fourth quarter of 2024.
- Immunovant reported an earnings per share of -52 cents, falling short of the forecasted -43 cents by analysts.
- The company did not generate any revenue during the quarter.
Article printed from InvestorPlace Media
©2024 InvestorPlace Media, LLC
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.